The effects of DL-endopeptidase-producing probiotics on human intestinal NOD2 activation and intestinal barrier related functions: A randomized, single-blind clinical trial

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400085272

Enrollment

Unknown

Registered

2024-06-04

Start date

2024-06-04

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sub-health status

Interventions

placebo group:administered with placebo for 14 days

treatment group:administered with probiotics for 14 days

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Sub-healthy individuals aged 20-50 years (questionnaire screening); (2) voluntarily cooperate with the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Taking probiotics, antibiotics, laxatives, drugs to treat intestinal ulcers and other drugs in the past month, or having digestive system symptoms (constipation, abdominal pain, diarrhea, melena, blood in the stool, etc.). (2) other conditions that researchers think need to be excluded.

Design outcomes

Primary

Measure	Time frame
Indicators of intestinal permeability;The relative contents of feces NOD2 ligands;	—

Secondary

Measure	Time frame
serum inflammatory factors ;	—

Countries

China

Contacts

Public ContactHongwei Zhou

Zhujiang Hospital of Southern Medical University

hzhou@smu.edu.cn+86 20 6278 3355

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026